Trametinib boosts palbociclib’s efficacy in breast cancer via autophagy inhibition
Oncology Research · 2024
DOI: 10.32604/or.2024.046139 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Research, 2024. Verfasst von Anguo Wu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Sichuan Key Medical Laboratory of New Drug Discovery and Druggability Evaluation, Luzhou Key Laboratory of Activity Screening and Druggability Evalua…. Hauptthemen laut MEDLINE: Autophagy, Breast Neoplasms, Pyridines, Pyridones. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Breast cancer, a predominant global health issue, requires ongoing exploration of new therapeutic strategies. Palbociclib (PAL), a well-known cyclin-dependent kinase (CDK) inhibitor, plays a critical role in breast cancer treatment. While its efficacy is recognized, the interplay between PAL and cellular autophagy, particularly in the context of the RAF/MEK/ERK signaling pathway, remains insufficiently explored. This study investigates PAL's inhibitory effects on breast cancer using both in vitro (MCF7 and MDA-MB-468 cells) and in vivo (tumor-bearing nude mice) models. Aimed at elucidating the impact of PAL on autophagic processes and exploring the potential of combining it with trametinib (TRA), an MEK inhibitor, our research seeks to address the challenge of PAL-induced drug resistance. Our findings reveal that PAL significantly decreases the viability of MCF7 and MDA-MB-468 cells and reduces tumor size in mice while showing minimal cytotoxicity in MCF10A cells. However, PAL also induces protective autophagy, potentially leading to drug resistance via the RAF/MEK/ERK pathway activation. Introducing TRA effectively neutralized this autophagy, enhancing PAL's anti-tumor efficacy. A combination of PAL and TRA synergistically reduced cell viability and proliferation, and in vivo studies showed notable tumor size reduction. In conclusion, the PAL and TRA combination emerges as a promising strategy for overcoming PAL-induced resistance, offering a new horizon in breast cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sichuan Key Medical Laboratory of New Drug Discovery and Druggability Evaluation, Luzhou Key Laboratory of Activity Screening and Druggability Evaluation for Chinese Materia Medica, Key Laboratory of Medical Electrophys…
- The Department of Pathology, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China.
- The Department of Pathology, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, 621000, China.
- The Department of Pathology, Yongchuan Hospital of Chongqing Medical University, Chongqing, 402160, China.
- School of Basic Medical Sciences, Southwest Medical University, Luzhou, 646000, China.
- School of Clinical Medical Sciences, Southwest Medical University, Luzhou, 646000, China.
Zitieren
APA
Wu, A., Yan, J., Su, T., Feng, C., Long, X., Pan, Y., Ye, R., Xia, T., Long, H., Wu, J., & Xiao, X. (2024). Trametinib boosts palbociclib’s efficacy in breast cancer via autophagy inhibition. Oncology Research. https://doi.org/10.32604/or.2024.046139
Vancouver
Wu A, Yan J, Su T, Feng C, Long X, Pan Y, et al. Trametinib boosts palbociclib’s efficacy in breast cancer via autophagy inhibition. Oncology Research. 2024. doi:10.32604/or.2024.046139
BibTeX
@article{Wu2024,
author = {Wu, Anguo and Yan, Jiao and Su, Ting and Feng, Chi and Long, Xin and Pan, Yiru and Ye, Rupei and Xia, Tian and Long, Hanan and Wu, Jianming and Xiao, Xiuli},
title = {Trametinib boosts palbociclib’s efficacy in breast cancer via autophagy inhibition},
journal = {Oncology Research},
year = {2024},
doi = {10.32604/or.2024.046139}
}
EUVIMED